Author:
Mlynáriková V.,Mičeková D.,Rovenský J.,Šteňová E.
Abstract
Abstract
Sjögren’s syndrome is a slowly progressive, inflammatory autoimmune disease primarily affecting exocrine glands. Lymphocytic infiltrates replace functional epithelium and lead to decreased exocrine secretion of salivary and lacrimal glands - xerocrinopathy. Glands of intestinal system and pulmonary tract, skin and vaginal mucosa may also be affected. The most common extraglandular manifestations of primary Sjögren’s syndrome include skin vasculitis, Raynaud’s phenomenon, functional renal abnormalities, neuropathy and arthritis symptoms. This disorder may appear separately as a primary Sjögren’s syndrome or in connection with other inflammatory rheumatic diseases as secondary Sjögren’s syndrome. Treatment of the disease is based on topical ocular and oral therapy, extraglandular manifestations need to be treated with hydroxychloroquine and severe cases even with corticosteroid or immunosuppressive drugs.
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference34 articles.
1. On knowledge of keratoconjuctivitis sicca Keatitis filiformis due to lacrimal gland hypofuncion;Sjögren;Acta Ophtalmol,1933
2. Sjögren syndrome associated with hepatitis C virus : a multicenter analysis of cases;Ramos;Medicine,2005
3. Long - term study of oral pilocarpine for the treatment of xerostomia associated with Sjögren s syndrome;Sugai;Jpn Pharmacol Ther,2007
4. Clinical manifestations and early diagnosis of Sjogrens syndrome;Kassan;Arch Intern Med,2004
5. Thyroid disease in primary Sjögren s syndrome : study in a series of patients;Ramos;Medicine,2000